The results from the BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer elimination) clinical trial in non-small cell lung cancer (NSCLC) undertaken at MD Anderson Cancer Center were recently published in the new AACR journal Cancer Discovery.
The BATTLE study is a landmark in that tumor biopsies were done in “real time” with adaptive randomization to erlotinib, vandetanib, erlotinib plus bexarotene or sorafenib based on relevant molecular biomarkers from the needle biopsy specimens.
Sally Church who did her doctoral research on the early detection of lung disease, has does an excellent job on Pharma Strategy Blog of reviewing the findings from this landmark clinical trial. She discusses the latest results presented by Dr Waun ki Hong in the plenary session at the recent AACR annual meeting in Orlando.
Using Storify to integrate multimedia about the BATTLE trial, Sally explains why this is a ground breaking study. You can read more on Pharma Strategy Blog.